Effect of the postprandial state on nontraditional risk factorsLEBOVITZ, Harold E.The American journal of cardiology. 2001, Vol 88, Num 6A, pp 20H-25H, issn 0002-9149Article

Metabolic consequences of atypical antipsychotic drugs : Medical illnesses and complications in psychiatric patientsLEBOVITZ, Harold E.Psychiatric quarterly. 2003, Vol 74, Num 3, pp 277-290, issn 0033-2720, 14 p.Article

A Symposium: The Postprandial State: Managing Its Atherogenic PotentialLEBOVITZ, Harold E.The American journal of cardiology. 2001, Vol 88, Num 6A, issn 0002-9149, 38 p.Serial Issue

Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 DiabetesLEBOVITZ, Harold E.Diabetes care. Supplement. 2011, Vol 34, Num 2, issn 1064-9131, S225-S230Article

Impaired glucose tolerance as a diseBARON, Alain D.The American journal of cardiology. 2001, Vol 88, Num 6A, pp 16H-19H, issn 0002-9149Article

Pathophysiologic mechanisms of postprandial hyperglycemiaGAVIN, James R.The American journal of cardiology. 2001, Vol 88, Num 6A, pp 4H-8H, issn 0002-9149Article

Rationale for and role of thiazolidinediones in type 2 diabetes mellitusLEBOVITZ, Harold E.The American journal of cardiology. 2002, Vol 90, Num 5A, pp 34G-41G, issn 0002-9149Conference Paper

The Postprandial Hyperglycaemic State: Emerging Concepts. Satellite SymposiumCHIASSON, Jean-Louis; LEBOVITZ, Harold E.Diabetes research and clinical practice. 1998, Vol 40, issn 0168-8227, 56 p., SUPConference Proceedings

Treatment of insulin resistance in diabetes mellitusLEBOVITZ, Harold E; BANERJI, Mary Ann.European journal of pharmacology. 2004, Vol 490, Num 1-3, pp 135-146, issn 0014-2999, 12 p.Article

Oral therapies for diabetic hyperglycemiaLEBOVITZ, Harold E.Endocrinology and metabolism clinics of North America. 2001, Vol 30, Num 4, issn 0889-8529, vii,909-933 [26 p.]Article

Controlling postprandial hyperglycemiaRATNER, Robert E.The American journal of cardiology. 2001, Vol 88, Num 6A, pp 26H-31H, issn 0002-9149Article

Asymptomatic hyperglycaemia and early atherosclerotic changesKAWAMORI, R.Diabetes research and clinical practice. 1998, Vol 40, pp S35-S42, issn 0168-8227, SUPConference Paper

Intermediate-density lipoproteins, diabetes and coronary artery diseaseSTEINER, G.Diabetes research and clinical practice. 1998, Vol 40, pp S29-S33, issn 0168-8227, SUPConference Paper

Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with ZiprasidoneWEIDEN, Peter J; NEWCOMER, John W; LOEBEL, Antony D et al.Neuropsychopharmacology (New York, NY). 2008, Vol 33, Num 5, pp 985-994, issn 0893-133X, 10 p.Article

Rosiglitazone monotherapy is effective in patients with type 2 diabetesLEBOVITZ, Harold E; DOLE, Jo F; PATWARDHAN, Rita et al.The Journal of clinical endocrinology and metabolism. 2001, Vol 86, Num 1, pp 280-288, issn 0021-972XArticle

Assessing the potential for α-glucosidase inhibitors in prediabetic statesHOLMAN, R. R.Diabetes research and clinical practice. 1998, Vol 40, pp S21-S25, issn 0168-8227, SUPConference Paper

Dysglycaemia : a cardiovascular risk factorGERSTEIN, H. C.Diabetes research and clinical practice. 1998, Vol 40, pp S9-S14, issn 0168-8227, SUPConference Paper

Impaired glucose tolerance : what are the clinical implications?ALBERTI, K. G. M. M.Diabetes research and clinical practice. 1998, Vol 40, pp S3-S8, issn 0168-8227, SUPConference Paper

Postprandial hyperglycaemia and α-glucosidase inhibitorsBARON, A. D.Diabetes research and clinical practice. 1998, Vol 40, pp S51-S55, issn 0168-8227, SUPConference Paper

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin MonotherapyFOUQUERAY, Pascale; PIRAGS, Valdis; DIAMANT, Michaela et al.Diabetes care. 2014, Vol 37, Num 7, pp 1924-1930, issn 0149-5992, 7 p.Article